March 30, 2018Journal of Nuclear Medicine29 citationsOpen Access
Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
Key Points
Key points are not available for this paper at this time.
Abstract
See the associated articles on pages 9091 and 9152. The last 2 years have brought significant progress for the clinical use of somatostatin receptor (SSR) targeted imaging and therapy in the United States. In 2016, the Food and Drug Administration approved 68Ga-DOTATATE for imaging of